Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759048 | 0.86 | GRM2 (0.69) | GRM2 | |
| SCHEMBL757530 | 0.86 | GRM2 (0.53) | GRM2KDM4EHPGD | |
| SCHEMBL4523612 | 0.81 | GRM2 (0.46) | GRM2KDM4EHPGDNPSR1RXFP1 | |
| SCHEMBL4523157 | 0.81 | GRM2 (0.43) | GRM2KDM4EHPGDNPSR1RXFP1 | |
| SCHEMBL4526619 | 0.79 | GRM2 (0.43) | GRM2KDM4EHPGDNPSR1RXFP1 | |
| SCHEMBL28057826 | 0.77 | GRM2 (0.73) | GRM2 | |
| SCHEMBL7803769 | 0.77 | ALOX5 (0.47) | GRM2ALOX5 | |
| SCHEMBL19610600 | 0.77 | GRM2 (0.48) | GRM2KDM4EHPGDNPSR1RXFP1 | |
| SCHEMBL756852 | 0.75 | GRM2 (0.54) | GRM2KDM4E | |
| SCHEMBL14921302 | 0.74 | GRM2 (0.65) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | US | disclosed |
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | US | disclosed |
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | US | disclosed |
| EP-1934205-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | Merck Frosst Canada Ltd. (CA) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, LTB4R2 | GRM2 4204/4885KDM4E 3147/4885HPGD 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.